SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharmaids Pharma - Quaterly Results

23 May 2025 Evaluate
The total revenue stands at Rs. 1.33 millions for the March 2025 quarter. The mentioned figure indicates an increase of about 1800.00% as against Rs. 0.07 millions during  the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -30.56 millions as compared to Net Loss of Rs. -22.38 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 further decreased to -16.75% as compared to -17.77% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1.33 0.07 1800.00 23.41 0.28 8260.71 23.41 0.28 8260.71
Other Income 10.07 0.31 3148.39 10.19 7.95 28.18 10.19 7.95 28.18
PBIDT -16.75 -17.77 -5.74 -62.38 -55.76 11.87 -62.38 -55.76 11.87
Interest 20.54 2.87 615.68 21.49 3.33 545.35 21.49 3.33 545.35
PBDT -37.29 -20.64 80.67 -83.87 -59.09 41.94 -83.87 -59.09 41.94
Depreciation 0.52 0.46 13.04 2.00 1.77 12.99 2.00 1.77 12.99
PBT -37.81 -21.10 79.19 -85.87 -60.86 41.09 -85.87 -60.86 41.09
TAX -7.25 1.28 -666.41 -13.08 -11.37 15.04 -13.08 -11.37 15.04
Deferred Tax -7.25 1.28 -666.41 -13.08 -11.37 15.04 -13.08 -11.37 15.04
PAT -30.56 -22.38 36.55 -72.79 -49.49 47.08 -72.79 -49.49 47.08
Equity 352.68 352.68 0.00 352.68 352.68 0.00 352.68 352.68 0.00
PBIDTM(%) -1259.40 -25385.71 -95.04 -266.47 -19914.29 -98.66 -266.47 -19914.29 -98.66

Pharmaids Pharma Share Price

30.92 -0.49 (-1.56%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×